[Etiology and treatment of malignancy-associated anaemia]
Patients with cancer frequently develop anaemia. Various factors, including the type of malignancy and the intensity of chemotherapy influence the prevalence of anaemia and need of transfusions. Among the numerous causes of its development, the most frequent type is cancer anaemia, the so-called "anaemia of chronic disorders". Anaemia of chronic disorders is diagnosed when neoplastic disease is accompanied by an otherwise unexplained microcytic anaemia with compromised iron utilisation and decreased erythropoietin secretion. In 50-70% of patients with solid tumors or hematological malignancies, mainly with multiple myeloma and malignant lymphomas, transfusion can be avoided, or significantly decreased by the use of recombinant erythropoietin. This review provides tools to decide the best candidates for this treatment and a guideline to monitor its efficacy.
Borbényi
Z
Z
2(nd) Department of Medicine and Center of Cardiology, Szeged University of Natural Sciences, Szeged, H-6701, Hungary. depart@inf.u-szeged.hu
A daganatos betegségekhez társuló anémiák okai és kezelési lehetôségei.